Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-29

Innovative chemokine-based therapeutic strategies for autoimmunity and chronic inflammation

Objetivo

The general objective of INNOCHEM is to develop innovative chemokine-based therapeutic strategies for autoimmunity and chronic inflammation. The project is based on the scientific excellence of the applicants, which have made major recognized contributions to the field since the very beginning of chemokine discovery, and on the construction of shared technological platforms.

This will include:
- proteomics and
- transcriptional profiling for the outline of the "chemokinome" in pathophysiological conditions and identification of new antagonists;
- molecular modelling of agonist/antagonist receptor or agonist/inhibitor interaction, for pharmacology and drug design; iv) gene modified mice for target validation in autoimmune disorders.

Genetic, structural, biological, and immunopathological studies will provide a framework for the development of innovative chemokine-based therapeutic strategies. The therapeutic approaches to be investigated are innovative and not limited to conventional antagonists. These will include decoy receptors, agonist binders, and non-competitive allosteric inhibitors. In addition to academic groups, therapy-oriented research will include 3 biotech SMEs, and 3 Pharma companies. The companies involved develop complementary non-overlapping approaches to target the chemokine system with recombinant and low molecular weight molecules.

INNOCHEM is expected to conduct a "proof of principle" clinical study in volunteers in the first 18 months. The ambition of this project is to re-establish European leadership in basic and applied chemokine research by integrating academic and industrial cutting edge groups to develop innovative therapeutic strategies against autoimmunity and chronic inflammatory disorders.

Convocatoria de propuestas

FP6-2004-LIFESCIHEALTH-5
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IP - Integrated Project

Coordinador

HUMANITAS MIRASOLE SPA
Aportación de la UE
Sin datos
Coste total
Sin datos

Participantes (28)